This protocol addresses Factor XI (FXI) deficiency in individuals who have developed FXI antibodies — commonly referred to as inhibitors. These inhibitors can cause significant inhibition and associated clinical problems, making standard replacement approaches insufficient.
Inhibitors are particularly likely to develop in people who are homozygous for the type II mutation, representing a distinct and clinically challenging sub-population within Hemophilia C.
When FXI inhibitors cannot be overcome, certain bypassing-agent strategies — drawn from experience managing inhibitors in related coagulation disorders — have been employed successfully in this setting.